RAPT Therapeutics Inc. (NASDAQ: RAPT) stock gained by 85.46% in the current market trading. RAPT Therapeutics is a clinical-stage immunology-based pharmaceutical business focusing on finding, developing, and promoting oral small molecule medicines for cancer and inflammatory disorders patients with large unmet needs.
RPT193 as monotherapy was found to be effective in 31 patients with moderate-to-chronic atopic dermatitis in a randomized placebo-controlled Phase 1b clinical study conducted by RAPT (AD). Patients with mild to chronic AD who received RPT193 saw a 36.3 percent improvement in the Eczema Area and Severity Index (EASI) score which is a common measure of disease severity, after four weeks of therapy, relative to 17.0 percent in the placebo group.
Moreover, the RPT193 group demonstrated significant and sustained improvement and increased separation from placebo in the two-week period following the conclusion of treatment, with a 53.2 percent improvement in EASI at the six-week time point compared to 9.6 percent in the placebo group. RPT193’s method of action, which is upstream of other medicines targeting cytokines or signaling pathways, might explain the sustained improvement.
In the Phase 1b trial, RPT193 was well received. There were no significant risk factors recorded, and all of those which had been reported were mild or moderate in severity. RPT193’s overall safety profile, which includes the Phase 1b trial and previously released blinded safety results from our Phase 1a trial in healthy volunteers, indicate that it is possibly the best oral medication that does not need laboratory safety monitoring.
Brian Wong, President and CEO of RAPT Therapeutics stated:
These findings significantly indicate RPT193’s potential as a viable, once-daily oral therapy for atopic dermatitis sufferers, which would be a promising therapeutic option to injectable medications. RPT193 will be tested in a Phase 2b study for atopic dermatitis and a Phase 2a study for asthma.